LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

Search

Verve Therapeutics Inc

Avatud

11.26 0.54

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.19

Max

11.28

Põhinäitajad

By Trading Economics

Sissetulek

19M

-31M

Müük

20M

33M

Aktsiakasum

-0.35

Kasumimarginaal

-94.108

Töötajad

274

EBITDA

19M

-35M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+34.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

604M

992M

Eelmine avamishind

10.72

Eelmine sulgemishind

11.26

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Verve Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuni 2025, 11:56 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17. juuni 2025, 14:02 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17. juuni 2025, 12:12 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17. juuni 2025, 11:01 UTC

Omandamised, ülevõtmised, äriostud

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17. juuni 2025, 10:47 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17. juuni 2025, 10:47 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17. juuni 2025, 10:46 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17. juuni 2025, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17. juuni 2025, 09:33 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Verve Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

34.34% tõus

12 kuu keskmine prognoos

Keskmine 15.06 USD  34.34%

Kõrge 24 USD

Madal 11 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Verve Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

4

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.1501 / 5.16Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.